With the CMSC 2021 annual meeting having wrapped up, the director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia offered his perspective on this year’s conference. [WATCH TIME: 1 minute]
David Li, MD, FRCPC
Advertisement
Professor of radiology, associate member in neurology, and director, Multiple Sclerosis/MRI Research Group, University of British Columbia
Articles by David Li, MD, FRCPC
The director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia spoke to some of the newer biomarkers and measures being assessed in the clinical management of multiple sclerosis. [WATCH TIME: 3 minutes]
The director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia spoke to the portable Standardized MRI Protocol card that is being distributed in an effort to better inform the community to follow the newly published guidelines. [WATCH TIME: 2 minutes]
MRI in MS, Takeaways for Clinicians and Neuroradiologists: Scott D. Newsome, DO; David Li, MD, FRCPC
In discussion regarding the new MRI consensus guidelines for patients with MS, Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss key points for their peers and colleagues.
Implementing new recommendations for the use of MRI in patients with MS will be a challenge in terms of education and adherence; Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss the next steps to increase awareness for both patients and providers.
Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss the impact of new MRI consensus guidelines for patients with multiple sclerosis.
Advertisement
Latest Updated Articles
Multiple Sclerosis MRI Protocol Card: David Li, MD, FRCPCPublished: October 26th 2021 | Updated:
MRI in MS, Takeaways for Clinicians and Neuroradiologists: Scott D. Newsome, DO; David Li, MD, FRCPCPublished: July 16th 2021 | Updated:
- CMSC 2021 Annual Meeting Takeaways: David Li, MD, FRCPC
Published: October 28th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
4
Reinforce Ocrelizumab’s Role Across the Full Spectrum of More Advanced Progressive MS: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
5
